Commentary

Video

Translating Metabolic Therapies Into Sarcoma

Author(s):

Brian A. Van Tine, MD, PhD

Brian A. Van Tine, MD, PhD, of Washington University of St. Louis and Siteman Cancer Center, discusses how to translate metabolic therapies into sarcoma management.

Brian A. Van Tine, MD, PhD, of Washington University of St. Louis and Siteman Cancer Center, discusses how to translate metabolic therapies into sarcoma management.

Related Videos
2 expert is featured in this series.
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Ann S. LaCasce, MD, MMSc
2 expert is featured in this series.
Estelamari Rodriguez, MD
2 expert is featured in this series.
2 expert is featured in this series.
Premal Thaker, MD, MS
Matthew Powell, MD
Related Content
OST-HER2 in lung-only metastatic osteosarcoma | Image Credit: © 2rogan - stock.adobe.com
January 16th 2025

OST-HER2 Meets Primary End Point of Phase 2b Trial in Lung-Only Metastatic Osteosarcoma

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Armin Ghobadi, MD
January 7th 2025

WT-7 Shows Acceptable Safety Profile in Relapsed/Refractory T-ALL/LBL

Explore the Latest Treatment Updates in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen V. Liu, MD
November 27th 2024

Explore the Latest Treatment Updates in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen V. Liu, MD

IMNN-01 Plus Perioperative Chemotherapy Maintains OS Benefit in Newly Diagnosed Advanced Ovarian Cancer
December 10th 2024

IMNN-001 Plus Perioperative Chemotherapy Maintains OS Benefit in Newly Diagnosed Advanced Ovarian Cancer

R. Lor Randall, MD, FACS
December 5th 2024

Preclinical Data Highlight YAP1 and KRAS as Drivers in Soft Tissue Sarcomas